Subscribe
Share
Share
Embed
Covering Ulcerative Colitis, Medical Device, Falsified Medicine, Toy Safety, Wet Macular Degeneration. This episode covers critical regulatory updates affecting Ulcerative Colitis, Medical Devices, Falsified Medicines, Toy Safety, and Wet Macular Degeneration across the EU, including cybersecurity vulnerabilities, product recalls, and new authorisations.
Regulatory news, updates, and insights for countries in the EU presented by the Carver Agents team
Welcome to Carver's European Union Regulatory Updates for March 02, 2026.
Starting with cybersecurity and technology updates in France, multiple vulnerabilities have been disclosed in Cisco Catalyst SD-WAN products. The critical vulnerability CVE-2026-20127 is actively exploited, allowing attackers to bypass security policies and gain unauthorized privileged access. Organizations are advised to migrate to maintained Cisco Catalyst SD-WAN versions with the latest security patches, perform detailed compromise investigations using recommended detection techniques, and monitor for indicators such as rogue peer connections, unauthorized SSH keys, system downgrades, and log tampering. Additionally, several other vulnerabilities affect Cisco Catalyst SD-WAN versions, with security patches forthcoming.
In France, multiple security vulnerabilities have also been reported in Mozilla products and Red Hat Linux kernels. Users must apply security patches promptly as detailed in Mozilla security bulletins mfsa2026-12 through mfsa2026-17 and Red Hat security bulletins referenced in the disclosures. Furthermore, Juniper Networks Junos OS Evolved versions are affected by a vulnerability permitting unauthenticated remote code execution. Users should apply patches according to Juniper Networks security bulletin JSA107128.
Trend Micro products in France are also impacted by multiple vulnerabilities that may lead to remote code execution and privilege escalation. The vendor’s security bulletin KA-0022458 provides guidance on patches and mitigation steps.
Turning to France’s product safety, the Directorate General for Competition, Consumer Affairs and Fraud Control, known as DGCCRF, has issued an alert regarding the presence of asbestos in sand-based toys. Professionals are instructed to suspend commercialization of all such toys until they are confirmed asbestos-free. Recalls have been initiated for affected products. Parents are advised not to buy or use sand-based toys currently owned due to the carcinogenic risks posed by asbestos, banned in France since 1997.
In France and its overseas territories including Martinique, Guadeloupe, Réunion, and Monaco, a new tax on small parcels valued under 150 euros will take effect from March 1, 2026. This tax requires a two-euro payment per article imported from outside the European Union. The VAT liable party, whether the seller or intermediary platform, is responsible for payment.
In Denmark and France, Penning Financial Services ApS has been granted a MiCA license by the Danish Financial Supervisory Authority, known as DFSA. Starting March 1, 2026, the firm is authorized to provide crypto-asset services in France under the free provision of services regime. Authorized services include custody, exchange, order execution, portfolio management, and transfer of crypto-assets, subject to compliance with French regulations.
In Germany, Philips Respironics has issued an Urgent Field Safety Notice regarding the discontinuation of the BiPAP A40 Pro device due to an unresolved alarm issue related to the oxygen sensor. Users are advised to continue use only under physician guidance or replace devices with alternatives. Healthcare providers must acknowledge the notice, complete and return the response form within 30 days, and distribute the information to relevant staff.
Also in Germany, Erbe Elektromedizin GmbH is recalling specific lots of single-use Flexible Cryoprobes due to a risk of rupture that can cause hearing loss and minor injuries. Customers must quarantine affected products, notify downstream users, and coordinate returns to mitigate health risks.
On pharmaceutical updates within the European Union, the European Medicines Agency has provided a summary for Entyvio, or vedolizumab, detailing its authorisation status, therapeutic indications, dosing, efficacy, safety profile, and risk management measures. Treatment initiation and supervision must be conducted by specialists experienced in the relevant diseases, with patient monitoring during and after infusion. Special alert cards summarizing safety information are to be provided to patients.
Additionally, Ranluspec, a biosimilar to Lucentis containing ranibizumab, has been authorised in the European Union for treatment of wet age-related macular degeneration, diabetic macular oedema, proliferative diabetic retinopathy, retinal vein occlusion, and choroidal neovascularisation. Administration must be by qualified eye doctors via intravitreal injection, following specified dosing intervals and monitoring protocols. Ranluspec is subject to additional monitoring with ongoing safety data collection.
In the United Kingdom, the Financial Conduct Authority has selected four firms to participate in its Regulatory Sandbox starting in the first quarter of 2026. These firms will trial stablecoin products focusing on issuance and use cases such as payments, wholesale settlement, and crypto trading. The FCA will use findings to shape final stablecoin regulations expected in 2026. Participating firms must prepare for authorization under the new cryptoasset regime effective October 2027 and ensure deposit-takers mitigate contagion risks between deposits, e-money, and regulated stablecoins.
The UK Medicines and Healthcare products Regulatory Agency, or MHRA, issued a safety roundup on February 25, 2026. It alerted healthcare professionals to falsified Mounjaro KwikPen 15mg pens, specifically batch D873576, which must not be supplied and should be quarantined and returned. Updated contraindications for the IXCHIQ Chikungunya vaccine now include age and comorbidity restrictions. Warnings on GLP-1 receptor agonists have been strengthened regarding risks of acute pancreatitis. Multiple medicine recalls and device notifications were also issued to ensure patient safety.
Also in the United Kingdom, a Class 2 recall was announced on February 23, 2026, for all batches of KidNaps Melatonin Oral Solution due to confirmed stability issues affecting product appearance and impurities. Wholesalers and pharmacies must stop supplying affected batches immediately, quarantine all stock, and return it to suppliers following approved procedures.
In the United Kingdom, a London construction company director received a suspended sentence, an unpaid work order, and a six-year director ban for fraudulently obtaining Covid Bounce Back Loans by exaggerating company turnover and misusing funds.
In Germany, regulatory authorities mandated updates to the Summary of Product Characteristics, package leaflets, and outer packaging for intravenous tranexamic acid products. These updates include warnings about the correct route of administration and new adverse reactions. Variations must be submitted by February 26, 2026, or by March 12, 2026, at the latest. A permanent, clearly visible warning is required on outer packaging to prevent medication errors.
Finally, in France, a series of administrative changes will take effect in March 2026. These include the introduction of a new tax on small parcels, automatic closure of certain PEL savings accounts, changes to municipal election dates and voting modalities, updates to family benefits and social leave, and adjustments to school calendars and professional indexes. Public bodies and affected individuals must adapt to these changes to ensure compliance and avoid penalties or missed benefits.
That wraps up today's regulatory updates. Visit carveragents.ai for more information.